Cannabis Law Report

AUGUST 17, 2021

Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

MAY 10, 2022

11 May 2022. First academic study of national medicinal cannabis data. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. The authors note, however, that the data doesn’t include patient outcomes. Here’s the Uni of Sydney press release.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

SEPTEMBER 12, 2022

08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. VANCOUVER, British Columbia, Sept. Penis Envy. Blue Pulaski.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

MAY 29, 2022

Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

DECEMBER 26, 2021

Along with the previously completed in vitro assays, these studies serve as the benchmark for further preclinical work in 2022 and will contribute to regulatory submissions as the company advances its DMT program. EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Veriheal

MARCH 23, 2023

The report states that the revision is an essential move for ensuring the legal use of cannabis-derived epilepsy drug Epidiolex , which is currently being reviewed as part of a series of clinical trials in Japan. Within the space of a few years, Japan’s cannabis market has quadrupled in size.

Legalization 81

Legalization Marijuana Clinical Trials Seed-To-Sale 81

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. Through the right mix of regulation, technology, and data, both are equally achievable,” says NPA CEO Britt Rollins. ABOUT MAYA.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MAY 14, 2022

13 May 2022. By 2022, it is now difficult to find a high street or retail centre between John o’ Groats and Land’s End without CBD products for sale. Canpain is planned to run for three years and aims to conduct clinical trials involving up to 5,000 patients suffering from chronic pain. BCL Solicitors LLP.

Access 52

Access CBD Research and Development Medicine 52

Cannabis Law Report

AUGUST 18, 2022

As research into the use of psychedelic therapies continues to expand and additional data demonstrate significant positive outcomes in the treatment of mental health conditions, the benefits that psychedelics offer will continue to gain acceptance and understanding across the medical community. .” BUFFALO, N.Y. , Aug.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The trial’s secondary endpoints including pharmacokinetics, genotyping, Neuropsychiatric Inventory (NPI), and measurement of suicide severity, have also been completed.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

The Cannigma

JUNE 23, 2022

In the 2022 Oregon State University Study , the cannabinoid acids were found to bind to the spike proteins on the virus which are used to gain entry into the host or human cell. He noted, “The data in the study isn’t really ready for translation to the clinic.” Common cannabinoids in cannabis. CBGA and COVID-19.

Cannabinoids 113

Cannabinoids Research and Development Clinical Trials Extraction 113

Cannabis Law Report

SEPTEMBER 2, 2021

“Suffolk County Community College joins new safeCircle client The City University of New York, as well as several existing higher education institution clients, who have turned to us for COVID-19 testing to support their 2021-2022 academic year,” stated Dr. James A. Hayward, president and CEO of Applied DNA. “As

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

DECEMBER 6, 2021

“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. About Oravax Medical.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Advancements in IP and Drug Development.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: [link] Accessed October 17, 2022. 2020;12(7):1935.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Data To Support Regulatory Filings in the United States. a leading clinical trial services company, for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee. BERWYN, Pa.–(BUSINESS Forward-Looking Statement.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Project CBD

FEBRUARY 27, 2023

Researchers have been investigating the use of cannabis to treat fibromyalgia’s constellation of symptoms for decades, with early clinical trials in the 2000s 1-4 suggesting a possible benefit of both pure THC and flower in managing the disease. It’s not a new idea.

THC 144

THC CBD Sleep Clinical Trials 144

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Programs shall train students in the fiduciary duties that facilitators owe clients and the consequences of breaching those duties.

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

DECEMBER 21, 2021

The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 52

Research and Development Supply Chain Data Business 52

Veriheal

MAY 16, 2022

Based on preclinical data results and five case studies in PD patients, University of Arizona associate professors Scott Sherman, MD, Ph.D., At the current time, researchers are busy carrying out a small-scale Phase I clinical trial into ketamine for PD. and Torsten Falk, Ph.D.,

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

JANUARY 3, 2022

Affirms expectations for initial topline results in 1H 2022. regulatory path; company expects to submit IND in 1Q 2022. We continue to anticipate reporting initial topline results from Part A of this trial in the first half of 2022, as we closely monitor the impact of COVID-19. Chief Executive Officer of Anebulo.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

NOVEMBER 12, 2021

As set out above, the Company understands that Brown Shipley is unable to exercise its security over the Pledged Shares until 1 July 2022 and has been informed that KCP are in discussions with Brown Shipley about removing the Pledged Shares from the Charge and will update the market accordingly. A PDMR form is set out below. 198,466,493.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

The Cannigma

JANUARY 13, 2023

While migraines are a commonly reported condition by patients in cannabis studies, there is little clinical research on how cannabis can influence migraine pain. Russo concluded the evidence he examined “supports experimental protocols of cannabis usage in migraine treatment should go forward employing modern controlled clinical trials.”

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

NOVEMBER 29, 2021

The potential real-life impact – keeping in mind that these data were generated under stringent clinical trial conditions and without any tailoring to the specific needs of the individual – could be even more transformative for those patients suffering from TRD.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. The studies are expected to begin in January of 2022. About Virpax Pharmaceuticals.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022. dollars in thousands (except for share and per share data). . . Financial Results. September 30, . .

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

NOVEMBER 15, 2021

The Company is developing this product candidate as a prophylactic treatment against SARS and influenza and has engaged Syneos Health to assist with the optimal clinical trial design. Sinclair is expected to begin the preclinical animal studies at the beginning of 2022 as part of the enabling trials for an IND application with the FDA.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

MAY 1, 2022

April 20, 2022. The potential for OHA to deny or delay approval to entheogenic practitioners who apply for training program approval because they lack access to a licensed service center to satisfy the required practicum. Finally, our committee kindly requests a meeting with the OHA to discuss our concerns and strategize on solutions.

Safety 52

Safety History Programs Clinical Trials 52

The Cannigma

FEBRUARY 1, 2023

To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. While RSO has been subject to increased popularity in treating certain types of cancers, no clinical trials have tested the safety or efficacy of RSO in humans, meaning that all evidence is anecdotal.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. In the US, hopes of a quick federal cannabis legalisation in 2022 are fading, but a long shot such as cannabis having a major impact on COVID transmission or remission could speed things up.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Radicle Real World Sleep results will be announced in early 2022. “We

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

DECEMBER 7, 2021

A full report of the anonymized, aggregate findings will be released in early 2022. Initial findings indicate a significant number of participants experienced clinically meaningful improvements, meaning they realized distinct and palpable improvements in quality of life through improvements in the respective health outcomes studied.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52